NCGC00378430

Research use only, not for human use.

NCGC00378430 is a potent?SIX1/EYA2?interaction inhibitor that disrupts the SIX1/EYA2 complex, EMT, and Metastasis.

NCGC00378430 is a potent?SIX1/EYA2?interaction inhibitor that disrupts the SIX1/EYA2 complex, EMT, and Metastasis.

Western Blot Analysis Cell Line:T47D cells Concentration:20 μM Incubation Time:3 days Result:Blocked TGF-β induced activation of p-Smad3, upregulation of FN1, and downregulation of E-CAD.

Animal Model:6-8 week old NSG mice with MCF7 tumor cellsDosage:25 mg/kg Administration:Local Injection to the site of tumor; every other day; from day 3 until the day 21 Result:Dramatically decreased distant metastatic burden compared to vehicle treatment.Had no growth inhibitory effect.Animal Model:Mice Dosage:20 mg/kg (Pharmacokinetic Analysis) Administration:IV Result:Had a T1/2α of 0.25 hours, a CL of 6.19 L/hr?kg, a Vss of 4.08 L/kg, a Cmax of 6703 ng/mL and an AUC of 3234 ng/mL?hr.

——

Others

Other Targets

SIX1-EYA2

——

——

920650-00-6

441.5

C22H23N3O5S

>98% (HPLC)

DMSO:90 mg/mL?(203.85 mM;?Need ultrasonic)

O=C(NC1=CC=C(OC)C(S(=O)(N2CCOCC2)=O)=C1)C3=CC=CC(N4C=CC=C4)=C3

——

(-20℃)

With Ice Pack

≥ 2 years